Skip to content
Home/Research/CJC-1295 (no DAC) / Mod GRF 1-29

CJC-1295 (no DAC) / Mod GRF 1-29 Research & Studies

We track 15 published, PubMed-indexed studies for CJC-1295 (no DAC) / Mod GRF 1-29, spanning 1985 to 2019. The research below includes 13 research articles, 2 clinical trials.

View CJC-1295 (no DAC) / Mod GRF 1-29 details, dosing & pricing →
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
13
Research Articles
2
Clinical Trials

Glycine-modified growth hormone secretagogues identified in seized doping material.

Research Article
Gajda PM, Holm NB, et al.|Drug Test Anal|2019
PubMed (PMID: 30136411)DOI: 10.1002/dta.2489

Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1-29).

Research Article
Youn YS, Na DH, et al.|J Chromatogr A|2004
PubMed (PMID: 15633743)DOI: 10.1016/j.chroma.2004.10.062

New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity.

Research Article
Toth K, Kovacs M, et al.|J Pept Res|1998
PubMed (PMID: 9516049)DOI: 10.1111/j.1399-3011.1998.tb00631.x

Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells.

Research Article
Chen C, Farnworth P, et al.|Endocrine|1998
PubMed (PMID: 9798733)DOI: 10.1385/ENDO:9:1:71

The somatotropic axis in neonatal calves can be modulated by nutrition, growth hormone, and Long-R3-IGF-I.

Research Article
Hammon H, Blum JW|Am J Physiol|1997
PubMed (PMID: 9252489)DOI: 10.1152/ajpendo.1997.273.1.E130

Study of the activation mechanism of human GRF(1-29)NH2 on rat mast cell histamine release.

Research Article
Estévez MD, Alfonso A, et al.|Inflamm Res|1995
PubMed (PMID: 7544679)DOI: 10.1007/BF01793219

Radiation and neuroregulatory control of growth hormone secretion.

Research Article
Ogilvy-Stuart AL, Wallace WH, Shalet SM|Clin Endocrinol (Oxf)|1994
PubMed (PMID: 7923820)DOI: 10.1111/j.1365-2265.1994.tb02525.x

Studies on alpha 2-adrenergic modulation of hypothalamic somatostatin secretion in rats.

Research Article
Lima L, Arce V, et al.|Life Sci|1993
PubMed (PMID: 8102470)DOI: 10.1016/0024-3205(93)90277-a

Clonidine pretreatment modifies the growth hormone secretory pattern induced by short-term continuous GRF infusion in normal man.

Clinical Trial
Lima L, Arce V, et al.|Clin Endocrinol (Oxf)|1991
PubMed (PMID: 1934527)DOI: 10.1111/j.1365-2265.1991.tb03510.x

Role of growth hormone-releasing hormone on pentagastrin-induced growth hormone release in normal subjects.

Research Article
Garcia-Rojas JF, Mangas A, et al.|J Endocrinol Invest|1991
PubMed (PMID: 2071825)DOI: 10.1007/BF03346800

Effects of a chronic GRF treatment on lambs having low or normal birth weight.

Research Article
Pastoureau P, Charrier J, et al.|Domest Anim Endocrinol|1989
PubMed (PMID: 2515938)DOI: 10.1016/0739-7240(89)90026-x

Effects of active immunization against somatostatin on serum growth hormone concentration in growing pigs: influence of fasting and repetitive somatocrinin injections.

Research Article
Dubreuil P, Pelletier G, et al.|Endocrinology|1989
PubMed (PMID: 2569391)DOI: 10.1210/endo-125-3-1378

Peptide histidine isoleucine and vasoactive intestinal polypeptide cause relaxation of opossum internal anal sphincter via two distinct receptors.

Research Article
Nurko S, Dunn BM, Rattan S|Gastroenterology|1989
PubMed (PMID: 2535995)DOI: 10.1016/0016-5085(89)91564-3

Influence of dopaminergic, adrenergic and cholinergic blockade and TRH administration on GH responses to GRF 1-29.

Clinical Trial
Jordan V, Dieguez C, et al.|Clin Endocrinol (Oxf)|1986
PubMed (PMID: 2871952)DOI: 10.1111/j.1365-2265.1986.tb03270.x

Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.

Research Article
Waelbroeck M, Robberecht P, et al.|Endocrinology|1985
PubMed (PMID: 2859987)DOI: 10.1210/endo-116-6-2643
View CJC-1295 (no DAC) / Mod GRF 1-29 Details← All Research